Antibodies, Monoclonal

Antibodies produced by a single clone of cells.
DrugDrug NameDrug Description
DB00002CetuximabAn endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.
DB00072TrastuzumabA monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.
DB00073RituximabA monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
DB00112BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in the treatment of many cancer types in combination with other antineoplastics.
DB05773Trastuzumab emtansineAn antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer.
DB06366PertuzumabAn antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents.
DB08935ObinutuzumabAn antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.
DB09037PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
DB00056Gemtuzumab ozogamicinA monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia.
DB00110PalivizumabA monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients.
DB00043OmalizumabA monoclonal anti-immunoglobulin E antibody used in the treatment of severe asthma and chronic idiopathic urticaria.
DB00051AdalimumabA monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
DB00065InfliximabA monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
DB00075MuromonabA monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients.
DB00087AlemtuzumabA monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.
DB00108NatalizumabA monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis.
DB00111DaclizumabA monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis.
DB01257EculizumabA recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
DB01270RanibizumabA recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
DB04949PexelizumabFor the treatment of inflammation during cardiac surgery.
DB04958EpratuzumabInvestigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
DB05097LabetuzumabLabetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab"
DB05101MatuzumabInvestigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.
DB05111FontolizumabInvestigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
DB05496OtelixizumabInvestigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.
DB05555EnokizumabInvestigated for use/treatment in asthma.
DB05595FarletuzumabInvestigated for use/treatment in ovarian cancer.
DB05656VeltuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's).
DB05679UstekinumabA targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis.
DB05797TNX-901Investigated for use/treatment in allergic reaction.
DB05889Inotuzumab ozogamicinAn antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL).
DB05892RI 624Investigated for use/treatment in pain (acute or chronic).
DB06116EldelumabInvestigated for use/treatment in ulcerative colitis.
DB05941LeronlimabInvestigated for use/treatment in HIV infection.
DB06192NimotuzumabInvestigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.
DB06273TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
DB06310MotavizumabInvestigated for use/treatment in viral infection and pediatric indications.
DB06317ElotuzumabAn antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents.
DB06318AVE9633Investigated for use/treatment in leukemia (myeloid).
DB06324XmAb 2513Investigated for use/treatment in lymphoma (unspecified) and lymphoma (non-hodgkin's).
DB06342Coltuximab ravtansineInvestigated for use/treatment in lymphoma (non-hodgkin's).
DB06360LucatumumabInvestigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).
DB06371SiplizumabInvestigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
DB06467ApolizumabInvestigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors.
DB06474SibrotuzumabInvestigated for use/treatment in cancer/tumors (unspecified), colorectal cancer, and lung cancer.
DB06550BivatuzumabInvestigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer.
DB06602ReslizumabAn IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults.
DB06606TeplizumabInvestigated for use/treatment in diabetes mellitus type 1.
DB06612MepolizumabAn IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults.
DB06643DenosumabA RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures.
DB08879BelimumabA B-lymphocyte stimulator (BLyS)-specific inhibitor that indirectly inhibits B cell survival, and is used to treat patients with autoantibody positive, active systemic lupus erythematosus.
DB08904Certolizumab pegolA tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
DB09033VedolizumabAn integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults with inadequate clinical response to immunomodulators.
DB09264IdarucizumabAn antibody that binds dabigatran for the reversal of anticoagulant effects of dabigatran.
DB11569IxekizumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
DB11715BapineuzumabBapineuzumab has been investigated for the treatment of Alzheimer's Disease.
DB11756SolanezumabSolanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
DB11767SarilumabA monoclonal antibody used to treat moderate to severe rheumatoid arthritis who have responded poorly or are intolerant of other DMARDs.
DB11849EmibetuzumabEmibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
DB11856LigelizumabLigelizumab has been used in trials studying the basic science and treatment of Asthma, Allergy, Peanut Allergy, Allergic Asthma, and Atopic Dermatitis, among others.
DB11862LandogrozumabLandogrozumab has been used in trials studying the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer.
DB11988OcrelizumabA CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis.
DB12053VisilizumabVisilizumab has been investigated for the treatment of Ulcerative Colitis.
DB12119GevokizumabGevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine...
DB12189EtrolizumabEtrolizumab has been used in trials studying the treatment of Crohn Disease and Ulcerative Colitis.
DB12213EtaracizumabEtaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.
DB12274AducanumabAducanumab has been used in trials studying the treatment of Alzheimer's Disease.
DB12335TanezumabTanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.
DB12456BococizumabBococizumab has been used in trials studying the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia.
DB12489Mirvetuximab SoravtansineMirvetuximab Soravtansine has been used in trials studying the treatment of Ovarian cancer, Endometrial Cancer, Fallopian tube cancer, Epithelial Ovarian Cancer, and Primary Peritoneal Cancer, among others.
DB12498MogamulizumabA monoclonal antibody used to treat relapsed or refractory mycosis fungoides or Sézary syndrome after attempting one other therapy.
DB12530InebilizumabInebilizumab has been used in trials studying the treatment of Blood Cancer, B-cell Malignancies, Advanced B Cell Malignancies, Chronic Lymphocytic Leukemia (CLL), and Diffuse Large B-Cell Lymphoma (DLBCL).
DB12560BlosozumabBlosozumab has been used in trials studying the basic science and treatment of Osteoporosis and Osteoporosis, Postmenopausal.
DB12589DacetuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma.
DB12609TovetumabTovetumab has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Advanced Solid Malignancies.
DB12734DemcizumabDemcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
DB12775AbituzumabAbituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic.
DB12820ConcizumabConcizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder.
DB12826DepatuxizumabDepatuxizumab has been used in trials studying the treatment and diagnostic of Adenocarcinoma and Advanced Solid Tumors.
DB12844RontalizumabRontalizumab has been used in trials studying the treatment of Systemic Lupus Erythematosus.
DB12849ClazakizumabClazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
DB12891OzanezumabOzanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting.
DB12893Sacituzumab govitecanSacituzumab govitecan has been used in trials studying the treatment of Breast Cancer, Cervical Cancer, Renal Cell Cancer, Colorectal Cancer, and Esophageal Cancer, among others.
DB12943MilatuzumabMilatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
DB13127OlokizumabOlokizumab has been used in trials studying the treatment of Crohn's Disease.
DB13923EmicizumabAn antibody against Factor IXa and Factor X used to treat hemophilia A.
DB13976SulesomabMarket product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
DB13979BesilesomabA monoclonal antibody bound to technetium-99 used to find infection and inflammation in patients with suspected osteomyelitis.
DB01269PanitumumabA recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
DB05578RamucirumabAn antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.
DB06186IpilimumabA human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
DB06607CatumaxomabFor use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label].
DB06650OfatumumabA CD20 inhibitor used for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
DB08870Brentuximab vedotinA CD30-directed antibody-drug conjugate used to treat various types of lymphoma.
DB09035NivolumabA PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
DB09052BlinatumomabAn antineoplastic antibody used to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
DB09077DinutuximabAn immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
DB09559NecitumumabA monoclonal antibody used to treat metastatic squamous non-small cell lung cancer.
DB13375EdrecolomabNot Annotated
DB11731Depatuxizumab mafodotinNo approved indication.
DB06674GolimumabA TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
DB00095EfalizumabA monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis.
DB09302AlirocumabA PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C).
DB09303EvolocumabA PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures.
DB09331DaratumumabA CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma.
DB11595AtezolizumabA monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
DB11776BrodalumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
DB11945AvelumabA monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
DB11714DurvalumabA monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer.
DB12159DupilumabA monoclonal antibody used to treat moderate to severe atopic dermatitis, asthma, and nasal polyps accompanied by chronic rhinosinusitis in adolescents and adults.
DB14597LanadelumabA plasma kallikrein inhibitor used to treat attacks of hereditary angioedema.
DB14042GalcanezumabA calcitonin-gene related peptide antagonist used to prevent migraines and treat cluster headaches.
DB12023BenralizumabA monoclonal antibody used to treat eosinophilic asthma.
DB14724EmapalumabAn interferon gamma blocking antibody used to treat primary hemophagocytic lymphohistiocytosis.
DB11580RavulizumabA monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria.
DB06043OlaratumabA platelet-derived growth factor receptor alpha blocking antibody used with doxorubicin to treat patients with certain types of soft tissue sarcoma (STS).
DB14762RisankizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
DB14811IsatuximabIsatuximab is under investigation in clinical trial NCT02514668 (A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma).
DB14877LintuzumabLintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
DB14907Bevacizumab zirconium Zr-89Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).
DB14908RefanezumabRefanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).
DB14997PateclizumabPateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in...
DB15101TigatuzumabTigatuzumab is under investigation in clinical trial NCT00991796 (CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)).
DB15135PonezumabPonezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
DB15397GMA-161GMA-161 is under investigation in clinical trial NCT00244257 (Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)).
DB15432Pinatuzumab vedotinPinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With...
DB15453Naratuximab emtansineNaratuximab emtansine is under investigation in clinical trial NCT01534715 (IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia).
DB14947BermekimabBermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).
DB14012BurosumabA fibroblast growth factor 23 blocking antibody used to treat X-linked hypophosphatemia.
DB00054AbciximabA monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.
DB00074BasiliximabA monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients.
DB11884Vadastuximab TalirineVadastuximab Talirine has been used in trials studying the treatment of Acute myeloid leukemia, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, and Acute Promyelocytic Leukemia.
DB12152SimtuzumabSimtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis.
DB12157FasinumabFasinumab has been used in trials studying the basic science and treatment of Sciatica, Back Pain, Low Back Pain, Osteoarthritis, Hip, and Abdominal Pain Upper, among others.
DB12331Labetuzumab govitecanLabetuzumab govitecan has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, and Metastatic Colorectal Cancer.
DB12683LumretuzumabLumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
DB12797EcromeximabEcromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma.
DB12917BimekizumabBimekizumab has been used in trials studying the treatment of Psoriatic arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, and Mild to Moderate Psoriasis.
DB13017Rovalpituzumab TesirineRovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
DB13073TregalizumabTregalizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
DB14039ErenumabA calcitonin-gene related peptide antagonist used to prevent migraines.
DB14040EptinezumabUse of eptinezumab is intended for migraine prevention [A33105, A33106, A33108].
DB14580BAN-2401BAN-2401 is an experimental drug that is currently in clinical trials for the treament of Alzheimer's disease.
DB14776CamrelizumabCamrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
DB14784GancotamabGancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
DB14843CodrituzumabCodrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma).
DB14864BrolucizumabAn anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.
DB14919RozanolixizumabRozanolixizumab is under investigation in clinical trial NCT03861481 (A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy).
DB14962Trastuzumab deruxtecanTrastuzumab deruxtecan is under investigation in clinical trial NCT02564900 (Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors).
DB15044TafasitamabTafasitamab is under investigation in clinical trial NCT02005289 (Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated...
DB15252NemolizumabNemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)).
DB15271CrizanlizumabA monoclonal antibody that targets selectin to reduce the frequency of vasooclusive crises in patients with sickle cell disease.
DrugDrug NameTargetType
DB00002CetuximabEpidermal growth factor receptortarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00002CetuximabComplement C1r subcomponenttarget
DB00002CetuximabComplement C1q subcomponent subunit Atarget
DB00002CetuximabComplement C1q subcomponent subunit Btarget
DB00002CetuximabComplement C1q subcomponent subunit Ctarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00002CetuximabComplement C1s subcomponenttarget
DB00002CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00072TrastuzumabComplement C1r subcomponenttarget
DB00072TrastuzumabComplement C1q subcomponent subunit Atarget
DB00072TrastuzumabComplement C1q subcomponent subunit Btarget
DB00072TrastuzumabComplement C1q subcomponent subunit Ctarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00072TrastuzumabComplement C1s subcomponenttarget
DB00072TrastuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00072TrastuzumabReceptor tyrosine-protein kinase erbB-2target
DB00072TrastuzumabEpidermal growth factor receptortarget
DB00073RituximabB-lymphocyte antigen CD20target
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00112BevacizumabComplement C1r subcomponenttarget
DB00112BevacizumabComplement C1q subcomponent subunit Atarget
DB00112BevacizumabComplement C1q subcomponent subunit Btarget
DB00112BevacizumabComplement C1q subcomponent subunit Ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00112BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabVascular endothelial growth factor Atarget
DB05773Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
DB05773Trastuzumab emtansineP-glycoprotein 1transporter
DB05773Trastuzumab emtansineCytochrome P450 3A4enzyme
DB05773Trastuzumab emtansineCytochrome P450 3A5enzyme
DB06366PertuzumabReceptor tyrosine-protein kinase erbB-2target
DB08935ObinutuzumabB-lymphocyte antigen CD20target
DB09037PembrolizumabProgrammed cell death protein 1target
DB00056Gemtuzumab ozogamicinMyeloid cell surface antigen CD33target
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00056Gemtuzumab ozogamicinComplement C1r subcomponenttarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Atarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Btarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Ctarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00056Gemtuzumab ozogamicinComplement C1s subcomponenttarget
DB00056Gemtuzumab ozogamicinHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00110PalivizumabFusion glycoprotein F0target
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00110PalivizumabComplement C1r subcomponenttarget
DB00110PalivizumabComplement C1q subcomponent subunit Atarget
DB00110PalivizumabComplement C1q subcomponent subunit Btarget
DB00110PalivizumabComplement C1q subcomponent subunit Ctarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00110PalivizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00043OmalizumabHigh affinity immunoglobulin epsilon receptor subunit alphatarget
DB00043OmalizumabHigh affinity immunoglobulin epsilon receptor subunit betatarget
DB00051AdalimumabTumor necrosis factortarget
DB00065InfliximabTumor necrosis factortarget
DB00075MuromonabT-cell surface glycoprotein CD3 epsilon chaintarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00075MuromonabComplement C1r subcomponenttarget
DB00075MuromonabComplement C1q subcomponent subunit Atarget
DB00075MuromonabComplement C1q subcomponent subunit Btarget
DB00075MuromonabComplement C1q subcomponent subunit Ctarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00075MuromonabComplement C1s subcomponenttarget
DB00075MuromonabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00075MuromonabT-cell surface glycoprotein CD3 delta chaintarget
DB00075MuromonabT-cell surface glycoprotein CD3 gamma chaintarget
DB00075MuromonabT-cell surface glycoprotein CD3 zeta chaintarget
DB00087AlemtuzumabCAMPATH-1 antigentarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00087AlemtuzumabComplement C1r subcomponenttarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Atarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Btarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Ctarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00087AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00108NatalizumabIntegrin alpha-4target
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00108NatalizumabComplement C1r subcomponenttarget
DB00108NatalizumabComplement C1q subcomponent subunit Atarget
DB00108NatalizumabComplement C1q subcomponent subunit Btarget
DB00108NatalizumabComplement C1q subcomponent subunit Ctarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00108NatalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00108NatalizumabIntercellular adhesion molecule 1target
DB00111DaclizumabInterleukin-2 receptor subunit alphatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00111DaclizumabComplement C1r subcomponenttarget
DB00111DaclizumabComplement C1q subcomponent subunit Atarget
DB00111DaclizumabComplement C1q subcomponent subunit Btarget
DB00111DaclizumabComplement C1q subcomponent subunit Ctarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00111DaclizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00111DaclizumabInterleukin-2 receptor subunit betatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB01257EculizumabComplement C5target
DB01270RanibizumabVascular endothelial growth factor Atarget
DB04958EpratuzumabB-cell receptor CD22target
DB05097LabetuzumabCarcinoembryonic antigen-related cell adhesion molecule 5target
DB05101MatuzumabEpidermal growth factor receptortarget
DB05111FontolizumabInterferon gammatarget
DB05595FarletuzumabFolate receptor alphatarget
DB05679UstekinumabInterleukin-12 subunit betatarget
DB05679UstekinumabInterleukin-23target
DB05797TNX-901High affinity immunoglobulin epsilon receptor subunit alphatarget
DB05889Inotuzumab ozogamicinP-glycoprotein 1transporter
DB05889Inotuzumab ozogamicinB-cell receptor CD22target
DB05892RI 624Beta-nerve growth factortarget
DB06116EldelumabC-X-C motif chemokine 10target
DB05941LeronlimabC-C chemokine receptor type 5target
DB06273TocilizumabInterleukin-6 receptor subunit alphatarget
DB06273TocilizumabCytochrome P450 3A4enzyme
DB06317ElotuzumabSLAM family member 7target
DB06318AVE9633Myeloid cell surface antigen CD33target
DB06318AVE9633Cytochrome P450 3A4enzyme
DB06324XmAb 2513Tumor necrosis factor receptor superfamily member 8target
DB06342Coltuximab ravtansineB-lymphocyte antigen CD19target
DB06342Coltuximab ravtansineCytochrome P450 3A4enzyme
DB06360LucatumumabTumor necrosis factor receptor superfamily member 5target
DB06371SiplizumabT-cell surface antigen CD2target
DB06474SibrotuzumabSeprasetarget
DB06550BivatuzumabCD44 antigentarget
DB06602ReslizumabInterleukin-5target
DB06612MepolizumabInterleukin-5target
DB06643DenosumabTumor necrosis factor ligand superfamily member 11target
DB08879BelimumabTumor necrosis factor ligand superfamily member 13Btarget
DB08904Certolizumab pegolTumor necrosis factortarget
DB08904Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
DB09033VedolizumabIntegrin alpha-4target
DB09033VedolizumabIntegrin beta-7target
DB11569IxekizumabInterleukin-17Atarget
DB11767SarilumabAlanine aminotransferase 1enzyme
DB11767SarilumabAlanine aminotransferase 2enzyme
DB11767SarilumabAspartate aminotransferaseenzyme
DB11767SarilumabCytochrome P450 3A4enzyme
DB11767SarilumabInterleukin-6 receptor subunit alphatarget
DB11767SarilumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB11988OcrelizumabB-lymphocyte antigen CD20target
DB12119GevokizumabInterleukin-1 betatarget
DB12489Mirvetuximab SoravtansineCytochrome P450 3A4enzyme
DB12498MogamulizumabC-X-C chemokine receptor type 4target
DB12589DacetuzumabTumor necrosis factor receptor superfamily member 5target
DB13923EmicizumabCoagulation factor IXtarget
DB13923EmicizumabCoagulation factor Xtarget
DB13979BesilesomabCarcinoembryonic antigentarget
DB01269PanitumumabEpidermal growth factor receptortarget
DB05578RamucirumabVascular endothelial growth factor receptor 2target
DB06186IpilimumabCytotoxic T-lymphocyte protein 4target
DB06607CatumaxomabEpithelial cell adhesion moleculetarget
DB06607CatumaxomabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB06607CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB06607CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB06607CatumaxomabT-cell surface glycoprotein CD3 epsilon chaintarget
DB06607CatumaxomabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB06650OfatumumabB-lymphocyte antigen CD20target
DB08870Brentuximab vedotinTumor necrosis factor receptor superfamily member 8target
DB08870Brentuximab vedotinCytochrome P450 3A4enzyme
DB08870Brentuximab vedotinATP-binding cassette sub-family B member 5transporter
DB09035NivolumabProgrammed cell death protein 1target
DB09052BlinatumomabB-lymphocyte antigen CD19target
DB09052BlinatumomabT-cell surface glycoprotein CD3 delta chaintarget
DB09077DinutuximabGanglioside GD2target
DB09559NecitumumabEpidermal growth factor receptortarget
DB11731Depatuxizumab mafodotinEpidermal growth factor receptortarget
DB11731Depatuxizumab mafodotinTubulin beta chaintarget
DB06674GolimumabTumor necrosis factortarget
DB00095EfalizumabIntegrin alpha-Ltarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00095EfalizumabComplement C1r subcomponenttarget
DB00095EfalizumabComplement C1q subcomponent subunit Atarget
DB00095EfalizumabComplement C1q subcomponent subunit Btarget
DB00095EfalizumabComplement C1q subcomponent subunit Ctarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00095EfalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB09302AlirocumabProprotein convertase subtilisin/kexin type 9target
DB09303EvolocumabProprotein convertase subtilisin/kexin type 9enzyme
DB09331DaratumumabADP-ribosyl cyclase 1target
DB11595AtezolizumabProgrammed cell death 1 ligand 1target
DB11945AvelumabProgrammed cell death 1 ligand 1target
DB11714DurvalumabProgrammed cell death 1 ligand 1target
DB11714DurvalumabT-lymphocyte activation antigen CD80target
DB12159DupilumabInterleukin-4 receptor subunit alphatarget
DB14597LanadelumabPlasma kallikreintarget
DB14042GalcanezumabCalcitonin gene-related peptide 1target
DB14042GalcanezumabCalcitonin gene-related peptide 2target
DB12023BenralizumabInterleukin-5 receptor subunit alphatarget
DB12023BenralizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB14724EmapalumabInterferon gammatarget
DB11580RavulizumabComplement C5target
DB06043OlaratumabPlatelet-derived growth factor receptor alphatarget
DB14762RisankizumabInterleukin-23target
DB14012BurosumabFibroblast growth factor 23target
DB00054AbciximabIntegrin beta-3target
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00054AbciximabComplement C1r subcomponenttarget
DB00054AbciximabComplement C1q subcomponent subunit Atarget
DB00054AbciximabComplement C1q subcomponent subunit Btarget
DB00054AbciximabComplement C1q subcomponent subunit Ctarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00054AbciximabComplement C1s subcomponenttarget
DB00054AbciximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00054AbciximabIntegrin alpha-IIbtarget
DB00054AbciximabVitronectintarget
DB00074BasiliximabInterleukin-2 receptor subunit alphatarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00074BasiliximabComplement C1r subcomponenttarget
DB00074BasiliximabComplement C1q subcomponent subunit Atarget
DB00074BasiliximabComplement C1q subcomponent subunit Btarget
DB00074BasiliximabComplement C1q subcomponent subunit Ctarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00074BasiliximabComplement C1s subcomponenttarget
DB00074BasiliximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00074BasiliximabInterleukin-2 receptor subunit betatarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB14039ErenumabCalcitonin gene-related peptide type 1 receptortarget
DB14040EptinezumabCalcitonin gene-related peptide 1target
DB14040EptinezumabCalcitonin gene-related peptide 2target
DB14864BrolucizumabVascular endothelial growth factor Atarget
DB15271CrizanlizumabP-selectintarget